browse Browse

pac.dog pac.dog / Lobbying

1st Quarter - Report · 2026

Filing UUID
92b19304-372c-4f3d-aa85-a58d4570e0bb
Type
Q1 — 1st Quarter - Report
Period
first_quarter
Year
2026
Posted
2026-04-20 22:36:26
Income (reported)
Expenses (reported)
$480,000
Expenses method
A
Filing document
Open on lda.senate.gov
Registrant (lobbying firm)

AKEBIA THERAPEUTICS, INC.

biopharmaceutical company

Contact
SARA FROELICH
Phone
+1 857-998-7068
Address
zip:02142, city:Cambridge, state:MA, street:245 First Street Suite 1100
Client

AKEBIA THERAPEUTICS, INC.

State
MA
Country
US
Government-entity client
false
Effective date
2018-07-01
Issues lobbied + lobbyists (2)

HCR — Health Issues

H.R. 2199/S. 1173, Restore Protections for Dialysis Patients Act H.R. 6214, Kidney Care Access Protection Act S. 2730, Kidney Care Access Protection Act Implementation of P.L. 118-14, Continuing Appropriations Act, 2024 and Other Extensions Act, including provisions related to Title III, Health and Human Services. Implications of Supreme Court Decision on Marietta v. DaVita on Medicare Secondary Payer (MSP) statute and commercial group health insurance. FY 2026 Appropriations for the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). Implementation of P.L. 118-158, the American Relief Act of 2025, including provisions relating to health care.

Lobbyists:

Government entities lobbied: Centers For Medicare and Medicaid Services (CMS); HOUSE OF REPRESENTATIVES; SENATE

MMM — Medicare/Medicaid

Implementation of the Inflation Reduction Act of 2022, P.L. 117-169, drug pricing provisions. Policy and technical issues related to the Medicare Advantage program and Medicare Part D prescription drug program. Center for Medicare and Medicaid Innovation (CMMI) mandatory and voluntary demonstration programs for patients with chronic kidney disease. CMSs inclusion of phosphate binders in the End Stage Renal Disease (ESRD) Prospective Payment System (PPS). Implementation of the 21st Century Cures Act of 2016, P.L. 114-255, extension of Medicare Advantage to Medicare ESRD patients. Final CY 2026 End Stage Renal Disease (ESRD) Prospective Payment System (PPS), Payment for Renal Dialysis Services Furnished to Individuals with Acute Kidney Injury (AKI), End Stage Renal Disease Quality Improvement Program (QIP), and End Stage Renal Disease Treatment Choices Model (ETC).

Lobbyists:

Government entities lobbied: Centers For Medicare and Medicaid Services (CMS); Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES; Office of Management & Budget (OMB); SENATE

pac.dog is a free, independent, non-partisan research tool. Every candidate, committee, bill, vote, member, and nonprofit on this site is mirrored from primary U.S. government sources (FEC, congress.gov, govinfo.gov, IRS) and each state's Secretary of State / election commission — no third-party data vendors, no paywall, no editorial intermediation. Citations to the originating source are on every detail page.